Feature: The 2026 vaccine licenses: influenza drives a new platform era

The most revealing feature of vaccine licensure in 2026 is not a newly targeted pathogen. It is the concentration of innovation around familiar respiratory threats: seasonal influenza and COVID-19. Four notable authorizations—Supemtek, mCombriax, mFlusiva and Aujemflu—are directed at influenza alone or influenza plus SARS-CoV-2. Collectively, they show a field establishing several innovative ways to improve a vaccine category whose public health importance is indisputable but whose performance, manufacturing and annual development within a very short time frame—from WHO strain selection to licensing and market availability—remain challenging. The products differ substantially. Two use lipid-nanoparticle-formulated mRNA; one is a recombinant protein vaccine; and one is a high-antigen-content, MF59-adjuvanted, cell-derived inactivated vaccine. Yet they share several design themes: an influenza focus, egg-independent or egg-avoiding production, an emphasis on adults aged 50 years and older, and a transition back to trivalent compositions after the global disappearance of B/Yamagata-lineage viruses. This is therefore less a story of...